@article{e1b7df9e6f7b4c45bdc71075392ba516,
title = "Liquid biopsies for residual disease and recurrence",
abstract = "Detection of minimal residual disease in patients with cancer, who are in complete remission with no cancer cells detectable, has the potential to improve recurrence-free survival through treatment selection. Studies analyzing circulating tumor DNA (ctDNA) in patients with solid tumors suggest the potential to accurately predict and detect relapse, enabling treatment strategies that may improve clinical outcomes. Over the past decade, assays for ctDNA detection in plasma samples have steadily increased in sensitivity and specificity. These are applied for the detection of residual disease after treatment and for earlier detection of recurrence. Novel clinical trials are now assessing how assays for “residual disease and recurrence” (RDR) may influence current treatment paradigms and potentially change the landscape of risk classification for cancer recurrence. In this review, we appraise the progress of RDR detection using ctDNA and consider the emerging role of liquid biopsy in the monitoring and management of solid tumors.",
keywords = "MRD, RDR, clinical trials, ctDNA, residual disease and recurrence, solid tumors",
author = "Wan, {Jonathan Chee Ming} and Mughal, {Tariq Imdadali} and Pedram Razavi and Dawson, {Sarah Jane} and Moss, {Esther Louise} and Ramaswamy Govindan and Tan, {Iain Beehuat} and Yap, {Yoon Sim} and Robinson, {William Allen} and Morris, {Clive Dylan} and Benjamin Besse and Alberto Bardelli and Jeanne Tie and Scott Kopetz and Nitzan Rosenfeld",
note = "Funding Information: This review is based on a series of clinical advisory meetings that took place in October and November 2020, supported by funding from Inivata, Inc., Research Triangle Park, NC, USA. The research leading to these results has received funding from the following: FONDAZIONE AIRC under 5 per Mille 2018 ? ID. 21091 program ? P.I. Bardelli Alberto (A.B.); AIRC under IG 2018 ? ID. 21923 project ? P.I. Bardelli Alberto (A.B.); and the International Accelerator Award, ACRCelerate, jointly funded by Cancer Research UK (A26825 and A28223), FC AECC (GEACC18004TAB), and AIRC (22795) (A.B.). J.C.M.W. T.I.M. and N.R. conceived and drafted the manuscript without any writing assistance provided by a third party. N.R. supervised the work. All other authors read the manuscript, edited the manuscript, and approved the final version of the manuscript. J.C.M.W. and N.R. are inventors/contributors on patents covering methods for ctDNA detection (including WO/2020/104670). P.R. reports institutional research funding from Novartis, Grail/Illumina, ArcherDx/Invitae, Inivata, Epic Sciences, and Tempus; advisory board/honoraria from Novartis, AstraZeneca, Foundation Medicine, Pfizer, Epic Sciences, Inivata, and Natera; and consulting for Tempus. Y.-S.Y. reports honoraria/consultancy from Novartis, Lilly, Pfizer, AstraZeneca, Eisai, MSD, and Specialised Therapeutics and travel support from Pfizer, Eisai, and Roche. S.-J.D. has received research funding from Roche Genentech and Cancer Therapeutics (CTx) CRC and has been an advisory board member for AstraZeneca and Inivata. S.K. serves on the advisory board and is a consultant for Inivata and Natera. N.R. and C.D.M. are officers of Inivata. T.I.M. P.R. E.L.M. R.G. I.T. Y.-S.Y. W.A.R. B.B. A.B. and J.T. served on the advisory board and consulted for Inivata. Funding Information: This review is based on a series of clinical advisory meetings that took place in October and November 2020, supported by funding from Inivata, Inc. , Research Triangle Park, NC, USA. The research leading to these results has received funding from the following: FONDAZIONE AIRC under 5 per Mille 2018 – ID. 21091 program – P.I. Bardelli Alberto (A.B.); AIRC under IG 2018 – ID. 21923 project – P.I. Bardelli Alberto (A.B.); and the International Accelerator Award, ACRCelerate, jointly funded by Cancer Research UK ( A26825 and A28223 ), FC AECC ( GEACC18004TAB ), and AIRC ( 22795 ) (A.B.). Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = dec,
day = "10",
doi = "10.1016/j.medj.2021.11.001",
language = "English",
volume = "2",
pages = "1292--1313",
journal = "Med",
issn = "2666-6359",
number = "12",
}